Hi NPH,
No, we didn't cover VolitionRx.
More on molecular (specifically, the epigenomics test) vs protein based tests (and the advantages of the latter - which I have already covered in previous posts).
I am aware of VolitionRx, though. Current MC of $73m vs RHY's $15m. And initial focus on the European market. They are focussing on multiple diagnostic products and have a few studies lined up for 2019. It is my understanding that the global market is easily large enough to accommodate competitors in this space. Might be a good idea to contact Glenn and have a chat about this point. Cheers.
An opinion on the commercial prospects of RHY, page-13
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5969 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 5500 | 1 |
View Market Depth
| Last trade - 16.16pm 18/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
Day chart unavailable
